source
- Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trialErasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
- China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slumpBiotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…